CCL

Összesen 32 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM033526
035-os BibID:PMID:20155824 WOS:000279432400036
Első szerző:Akhmetshina, Alfiya
Cím:Decreased lymphatic vessel counts in patients with systemic sclerosis : association with fingertip ulcers / Alfiya Akhmetshina, Jürgen Beer, Karin Zwerina, Matthias Englbrecht, Katrin Palumbo, Clara Dees, Nicole Reich, Jochen Zwerina, Gabriella Szucs, Johannes Gusinde, Tatiana Nevskaya, Oliver Distler, Dontscho Kerjaschki, Georg Schett, Jörg H. W. Distler
Dátum:2010
ISSN:0004-3591
Megjegyzések:Systemic sclerosis (SSc) is a connective tissue disease that is characterized by microvascular disease and tissue fibrosis. Progressive loss and irregular architecture of the small blood vessels are well characterized, but the potential involvement of the lymphatic vessel system has not been analyzed directly in SSc. This study was undertaken to assess whether the lymphatic vascular system is affected in SSc, and whether changes to the lymphatic vessels are associated with dystrophic changes and tissue damage in patients with SSc. METHODS: Lymphatic endothelial cells in skin biopsy samples from patients with SSc and age- and sex-matched healthy volunteers were identified by staining for podoplanin and prox-1, both of which are specifically expressed in lymphatic endothelial cells but not in blood vascular endothelial cells. CD31 was used as a pan-endothelial cell marker. Statistical analyses were performed using Kruskal-Wallis, Mann-Whitney U, and Spearman's rank correlation tests. RESULTS: The numbers of podoplanin- and prox-1-positive lymphatic vessels were significantly reduced in patients with SSc as compared with healthy individuals. The number of podoplanin-positive lymphatic precollector vessels was significantly lower in SSc patients with fingertip ulcers than in SSc patients without ulcers. Moreover, the number of lymphatic vessels correlated inversely with the number of fingertip ulcers at the time of biopsy and with the number of fingertip ulcers per year. The inverse correlation between lymphatic precollector vessel counts and fingertip ulcers remained significant after statistical adjustment for the blood vessel count, age, and modified Rodnan skin thickness score. CONCLUSION: These results demonstrate a severe reduction in the number of lymphatic capillaries and lymphatic precollector vessels in patients with SSc. Patients with decreased lymphatic vessel counts may be at particularly high risk of developing fingertip ulcers.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
külföldön készült közlemény
Megjelenés:Arthritis and Rheumatism. - 62 : 5 (2010), p. 1513-1522. -
További szerzők:Beer, Jürgen Zwerina, Karin Englbrecht, Matthias Palumbo, Katrin Dees, Clara Reich, Nicole Zwerina, Jochen Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Gusinde, Johannes Nevskaya, Tatiana Distler, Oliver Kerjaschki, Dontscho Schett, Georg Distler, Jörg H. W.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM033505
035-os BibID:PMID:18668558 WOS:000259055400042
Első szerző:Akhmetshina, Alfiya
Cím:Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts / Alfiya Akhmetshina, Clara Dees, Margarita Pileckyte, Gabriella Szucs, Bernd M. Spriewald, Jochen Zwerina, Oliver Distler, Georg Schett, Jörg H. W. Distler
Dátum:2008
ISSN:0004-3591
Megjegyzések:Rho-associated kinases (Rock) are the major cellular mediators of Rho GTPases and play an important role in the organization of the actin cytoskeleton. Inhibitors of Rock are currently being evaluated for the treatment of pulmonary arterial hypertension. This study was undertaken to analyze the role of Rock in the activation of fibroblasts in systemic sclerosis (SSc). METHODS: Rock signaling was inhibited using chemical inhibitors and small interfering RNA. The expression of extracellular matrix (ECM) proteins and alpha-smooth muscle actin was analyzed by real-time polymerase chain reaction, Western blotting, and SirCol assay. Metabolic activity was quantified by MTT assay. Cell viability was assessed by staining with annexin V and propidium iodide. The role of MAP kinases was investigated using selective inhibitors and Western blotting. RESULTS: Inhibition of Rock strongly reduced the synthesis of the major ECM proteins at the messenger RNA level as well as the protein level. Counterregulatory changes in the expression of tissue inhibitors of metalloproteinases and matrix metalloproteinases were not observed. Inhibition of Rock prevented myofibroblast differentiation. Transforming growth factor beta activated ERK in a Rock-dependent manner, and ERK mediated in part the stimulatory effects of Rock on myofibroblast differentiation. Toxic adverse effects of the inhibition of Rock were not observed. CONCLUSION: Our findings demonstrate that Rock potently stimulates the differentiation of resting fibroblasts into myofibroblasts and the production of ECM at biologically relevant concentrations without cell toxicity. These findings, along with the beneficial effects of Rock inhibition on vascular disease, indicate that inhibition of Rock might be an interesting novel therapeutic approach for the treatment of SSc.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
külföldön készült közlemény
Megjelenés:Arthritis And Rheumatism. - 58 : 8 (2008), p. 2553-2564. -
További szerzők:Dees, Clara Pileckyte, Margarita Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Spriewald, Bernd M. Zwerina, Jochen Distler, Oliver Schett, Georg Distler, Jörg H. W.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM053870
Első szerző:Bachmann, Michael
Cím:Somatic mutation : a novel mechanism for initiation of autoantibodies / Michael P. Bachmann, Imre Semsei, Joanne D. Gross, Timothy F. Gross, Judith A. James, John B. Harley
Dátum:2001
ISSN:0004-3591
Tárgyszavak:Orvostudományok Elméleti orvostudományok idézhető absztrakt
Megjelenés:Arthritis and Rheumatism. - 44 : 9 (2001), p. S273. -
További szerzők:Semsei Imre (1954-) (vegyész, gerontológus) Gross, Joanne K. Gross, Timothy F. James, Judith A. Harley, John B.
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

4.

001-es BibID:BIBFORM078908
Első szerző:Betteridge, Zoe
Cím:Clinical Phenotypes of Caucasian Adult and Juvenile Dermatomyositis Patients with Anti-MDA5 Autoantibodies / Zoe Betteridge, Sarah Tansley, Harsha Gunawardena, Lucy R. Wedderburn, Hector Chinoy, Robert G. Cooper, Jiri Vencovsky, Lenka Plestilova, Ingrid E. Lundberg, Katalin Danko, Melinda Vincze, Neil McHugh, UK JDRG, EuMyoNet
Dátum:2019
Megjegyzések:Background/Purpose: Autoantibodies to MDA5 have been previously reported in Japanese patients with dermatomyositis (DM) and are associated with clinically-amyopathic DM and rapidly progressing interstitial lung disease (ILD). These autoantibodies also occur in juvenile Japanese DM patients in association with ILD. Anti-MDA5 has also been reported in a cohort of mixed ethnicity, where it was found to be associated with ILD and severe vasculopathy. Here we report on the frequency and clinical manifestations of anti-MDA5 autoantibodies in a large international multicenter cohort of Caucasian adult and juvenile myositis patients. Methods: Serum was available from 1331 adult myositis patients (480 DM) recruited to the EuMyoNet repository and 172 JDM patients recruited to the UK JDRG. Sera were screened for autoantibodies by immunoprecipitation (IPP) using radio-labelled K562 cell extract. Sera with immunoprecipitates at approximately 140 kDa were tested for anti-MDA5 autoantibodies by ELISA using recombinant MDA5 (Cambridge BioSciences). Clinical data were collected on standardised proformas. Sera from 169 systemic sclerosis, 40 SLE and 50 healthy controls were also analyzed by IPP. Statistical analysis was performed using SPSS and Fishers Exact Test. Results: Anti-MDA5 autoantibodies were found in the sera of 12 JDM patients and 25 adults. The frequency in the JDM cohort was 7.0%, in comparison to 1.9% in the overall adult myositis population and 3.8% in the adult DM group. Anti-MDA5 autoantibodies were not found in any patients with PM or any control sera. As with previous reports, there was an association between ILD and anti-MDA5 (p_0.044) in the adultDMpatients. However, contrary to previous reports, this was not seen to be rapidly progressing, with no known ILD related fatalities in the anti-MDA5 positive group. In comparison, ILD was not found to be a significant association in the JDM anti-MDA5 positive group, with no patients having ILD reported as a clinical manifestation. Similarly to previous report, anti-MDA5 positive patients had significantly more ulceration (skin: p_0.047 and mouth: p_0.039), in the JDM cohort, compared with the anti-MDA5 negative group. Whilst ulceration data was unavailable in the adult population, the presence of anti-MDA5 was significantly associated with Gottron's papules (p_0.001). Conclusion: We report the presence of anti-MDA5 autoantibodies in a large cohort of Caucasian JDM and adult myositis patients. The frequency of anti-MDA5 autoantibodies varies between adults and children, along with differences in the clinical profile. As with previous reports, the presence of anti-MDA5 is associated with the presence of severe cutaneous features in both JDM and adults. However, in this study ILD was only an association in the adult population, suggesting differences in pathogenesis or aetiology. This study also highlights differences in clinical manifestations between different ethnic groups, with the ILD in our adult patients being
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
Megjelenés:Arthritis & Rheumatism. - 64 : 10 (2019), p. S715. -
További szerzők:Tansley, Sarah Gunawardena, Harsha Wedderburn, Lucy R. Chinoy, Hector Cooper, Robert G. Vencovsky, Jiri Plestilova, Lenka Lundberg, Ingrid Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Nagy-Vincze Melinda (1985-) (orvos) McHugh, Neil UK JDRG EuMyoNet
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM038593
Első szerző:Cervera, Ricard
Cím:Antiphospholipid syndrome : clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients / Ricard Cervera, Jean-Charles Piette, Josep Font, Munther A. Khamashta, Yehuda Shoenfeld, Maria Teresa Camps, Soren Jacobsen, Gabriella Lakos, Angela Tincani, Irene Kontopoulou-Griva, Mauro Galeazzi, Pier Luigi Meroni, Ronald H. W. M. Derksen, Philip G. de Groot, Erika Gromnica-Ihle, Marta Baleva, Marta Mosca, Stefano Bombardieri, Frédéric Houssiau, Jean-Christophe Gris, Isabelle Quéré, Eric Hachulla, Carlos Vasconcelos, Beate Roch, Antonio Fernández-Nebro, Marie-Claire Boffa, Graham R. V. Hughes, Miguel Ingelmo, Euro-Phospholipid Project Group
Dátum:2002
ISSN:0004-3591
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Arthritis And Rheumatism 46 : 4 (2002), p. 1019-1027. -
További szerzők:Piette, Jean-Charles Font, Josep Khamashta, Munther A. Shoenfeld, Yehuda Camps, Maria Teresa Jacobsen, Soren Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Tincani, Angela Kontopoulou-Griva, Irene Galeazzi, Mauro Meroni, Pier Luigi Derksen, Ronald H. W. M. de Groot, Philip G. Gromnica-Ihle, Erika Baleva, Marta Mosca, Marta Bombardieri, Stefano Houssiau, Frédéric Gris, Jean-Christophe Quéré, Isabelle Hachulla, Eric Vasconcelos, Carlos Roch, Beate Fernández-Nebro, Antonio Boffa, Marie-Claire Hughes, Graham R. V. Ingelmo, Miguel Soltész Pál (1961-) (belgyógyász, kardiológus) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Kiss Emese (1960-) (belgyógyász, immunológus) Euro-Phospholipid Project Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM038591
035-os BibID:PMID:16145672
Első szerző:Csípő István (vegyész)
Cím:Soluble complement receptor 1 (CD35) bound to immune complexes in sera of patients with systemic lupus erythematosus / István Csípő, Emese Kiss, Éva Bakó, Gyula Szegedi, Mária Kavai
Dátum:2005
ISSN:0004-3591
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Arthritis and Rheumatism. - 52 : 9 (2005), p. 2950-2951. -
További szerzők:Kiss Emese (1960-) (belgyógyász, immunológus) Bakó Éva (1958-) (biokémikus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kávai Mária (1930-) (vegyész)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

7.

001-es BibID:BIBFORM015816
Első szerző:Gerlag, Danielle M.
Cím:Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate / Gerlag, D. M., Hollis, S., Layton, M., Vencovsky, J., Szekanecz, Z., Braddock, M., Tak, P. P., The ESCAPE Study Group
Dátum:2010
ISSN:1529-0131 (Electronic)
Megjegyzések:To investigate both the preclinical effects of blocking the chemokine receptor CCR5 and the clinical effects of this approach on the signs and symptoms of rheumatoid arthritis (RA) in patients with active disease. METHODS: Preclinical evaluations of AZD5672, a small-molecule antagonist of CCR5, were performed, including studies of ligand binding and chemotaxis. The pharmacokinetics of AZD5672 were assessed in both single- and multiple-dose studies in healthy volunteers. A randomized, placebo-controlled, phase IIb study was conducted in patients with active RA receiving methotrexate. Treatment arms were AZD5672 (20, 50, 100, or 150 mg orally, once daily), matched placebo, or open-label etanercept (50 mg subcutaneously, once weekly). The primary end point was the proportion of patients achieving a 20% improvement response on the American College of Rheumatology improvement criteria (ACR20) at week 12. Secondary end points included the ACR20 over time, as well as 50% (ACR50) and 70% (ACR70) improvement responses, changes in individual components of the ACR improvement criteria, and disease activity measured with the Disease Activity Score based on the 28-joint count. RESULTS: AZD5672 was a highly potent and selective antagonist of CCR5, displaying nonproportional steady-state pharmacokinetics while inhibiting internalization of CCR5 in an ex vivo macrophage inflammatory protein 1beta stimulation assay in which AZD5672 was evaluated over the 20-150-mg dose range. In the phase IIb study testing this dose range in patients with RA (n = 371 patients randomized to received treatment), AZD5672 was generally well tolerated, with no unexpected adverse events. There was no statistically significant difference in the proportion of patients achieving an ACR20 response at week 12 between those receiving any dose of AZD5672 and those receiving placebo; etanercept was significantly more efficacious than AZD5672 and placebo. CONCLUSION: Despite a clear rationale for targeting CCR5, this clinical study showed that AZD5672, administered orally, did not have any clinical benefit, suggesting that CCR5 antagonism alone is unlikely to be a viable therapeutic strategy in RA.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Antirheumatic Agents/therapeutic use
Arthritis, Rheumatoid/*drug therapy
Benzeneacetamides/*therapeutic use
Chi-Square Distribution
Double-Blind Method
Drug Therapy, Combination
Female
Humans
Male
Methotrexate/*therapeutic use
Receptors, CCR5/*antagonists & inhibitors
Sulfonamides/*therapeutic use
Treatment Outcome
Megjelenés:Arthritis and Rheumatism. - 62 : 11 (2010), p. 3154-3160. -
További szerzők:Hollis, Sally Layton, Mark Vencovsky, Jiri Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Braddock, Martin Tak, Paul P. The ESCAPE Study Group
Internet cím:DOI
elektronikus változat
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM050381
035-os BibID:PMID:23653330
Első szerző:Glant Tibor T.
Cím:Differentially expressed epigenome modifiers, including aurora kinases A and B, in immune cells in rheumatoid arthritis in humans and mouse models / Tibor T. Glant, Timea Besenyei, András Kádár, Júlia Kurkó, Beata Tryniszewska, János Gál, Györgyi Soós, Zoltán Szekanecz, Gyula Hoffmann, Joel A. Block, Robert S. Katz, Katalin Mikecz, Tibor A. Rauch
Dátum:2013
ISSN:0004-3591
Megjegyzések:To identify epigenetic factors that are implicated in the pathogenesis of rheumatoid arthritis (RA), and to explore the therapeutic potential of the targeted inhibition of these factors. METHODS: Polymerase chain reaction (PCR) arrays were used to investigate the expression profile of genes that encode key epigenetic regulator enzymes. Mononuclear cells from RA patients and mice were monitored for gene expression changes, in association with arthritis development in murine models of RA. Selected genes were further characterized by quantitative reverse transcription-PCR, Western blot, and flow cytometry methods. The targeted inhibition of the up-regulated enzymes was studied in arthritic mice. RESULTS: A set of genes with arthritis-specific expression was identified by the PCR arrays. Aurora kinases A and B, both of which were highly expressed in arthritic mice and treatment-naive RA patients, were selected for detailed analysis. Elevated aurora kinase expression was accompanied by increased phosphorylation of histone H3, which promotes proliferation of T lymphocytes. Treatment with VX-680, a pan-aurora kinase inhibitor, promoted B cell apoptosis, provided significant protection against disease onset, and attenuated inflammatory reactions in arthritic mice. CONCLUSION: Arthritis development is accompanied by changes in expression of a number of epigenome-modifying enzymes. Drug-induced down-regulation of the aurora kinases, among other targets, seems to be sufficient to treat experimental arthritis. Development of new therapeutics that target aurora kinases can potentially improve RA management.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
epigenome modifiers
rheumatoid arthritis
Megjelenés:Arthritis and Rheumatism. - 65 : 7 (2013), p. 1725-1735. -
További szerzők:Besenyei Tímea (1980-) (reumatológus, belgyógyász) Kádár András (1977-) (belgyógyász) Kurkó Júlia Emese (1979-) (reumatológus) Tryniszewska Beáta Gál János Soós Györgyike (1959-) (pathológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Hoffmann Gyula Block, Joel A. Katz, Robert S. Mikecz Katalin Rauch Tibor A.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM039164
Első szerző:Glant Tibor T.
Cím:Cartilage-specific constitutive expression of TSG-6 protein (product of tumor necrosis factor alpha-stimulated gene 6) provides a chondroprotective, but not antiinflammatory, effect in antigen-induced arthritis / Glant, T. T., Kamath, R. V., Bardos, T., Gal, I., Szanto, S., Murad, Y. M., Sandy, J. D., Mort, J. S., Roughley, P. J., Mikecz, K.
Dátum:2002
ISSN:0004-3591
Megjegyzések:To study the chondroprotective effect of constitutively expressed TSG-6 protein (tumor necrosis factor alpha-induced protein 6; Tnfip6) in cartilage, using antigen-induced arthritis (AIA) in mice. METHODS: Transgenic mice constitutively expressing TSG-6 protein in cartilage were generated. Cartilage-specific constitutive expression of TSG-6 protein was confirmed by in situ hybridization, Western blot analysis, and immunohistochemistry. Control and transgenic mice were immunized with methylated bovine serum albumin (mBSA), and arthritis was induced by the intraarticular injection of mBSA. Mice were monitored up to day 35 after the challenge, and knee joint sections were examined for loss of cartilage proteoglycan (aggrecan) using Safranin O staining and antibodies to neoepitopes generated by various metalloproteinases (MPs). The loss of aggrecan in Safranin O-stained sections was quantified by morphometric methods. RESULTS: Tsg6/tnfip6 transgenic mice constitutively expressed tsg6/tnfip6 messenger RNA and corresponding TSG-6 protein in cartilage from embryonic life through adulthood, without any phenotypic abnormalities. These mice were used for AIA studies. Intraarticular injection of mBSA uniformly induced severe inflammation both in control (wild-type and an irrelevant transgenic line) mice and in tsg6/tnfip6 transgenic mice. In contrast to the mBSA-injected knee joints of control animals that were heavily damaged from day 5, the cartilage of transgenic mice that constitutively expressed TSG-6 protein remained intact for at least 1 week, and this was followed by a relatively reduced loss of aggrecan. Concomitant with the loss of aggrecan, MP-generated neoepitopes accumulated in unprotected joints. By day 35, the proteoglycan content returned to nearly normal levels in tsg6/tnfip6 transgenic mice, whereas it remained low in MP-damaged knee cartilage of control mice. CONCLUSION: TSG-6 protein is known to form a complex with inter-alpha-inhibitor (IalphaI), a potent serine protease inhibitor, which may be immobilized via the hyaluronan (HA)-binding domain of TSG-6 protein in the HA-rich extracellular matrix of cartilage. Thus, the local accumulation of TSG-6 protein and TSG-6 protein-bound IalphaI in tsg6/tnfip6 transgenic mice may inhibit serine proteases and subsequent activation of MPs. It is suggested that this mechanism might protect cartilage from extensive degradation even in the presence of acute inflammation.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Arthritis And Rheumatism. - 46 : 8 (2002), p. 2207-2218. -
További szerzők:Kamath, Rajesh V. Bárdos Tamás Gál István (1957-) (belgyógyász) Szántó Sándor (1968-) (belgyógyász, reumatológus) Murad, Yanal M. Sandy, John D. Mort, John S. Roughley, Peter J. Mikecz Katalin
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM046530
Első szerző:Hanyecz Anita
Cím:Achievement of a synergistic adjuvant effect on arthritis induction by activation of innate immunity and forcing the immune response toward the Th1 phenotype / Hanyecz, A., Berlo, S. E., Szanto, S., Broeren, C. P., Mikecz, K., Glant, T. T.
Dátum:2004
ISSN:0004-3591
Megjegyzések:To apply and analyze the mechanisms of action of dimethyldioctadecylammonium bromide (DDA), a powerful adjuvant that does not have the side effects of the conventionally used Freund's adjuvants, in proteoglycan-induced arthritis (PGIA) and collagen-induced arthritis (CIA). METHODS: PGIA and CIA were generated using standard immunization protocols with cartilage proteoglycan aggrecan (PG) or human type II collagen (CII) emulsified with Freund's complete adjuvant (CFA), and compared with PGIA and CIA generated using immunization protocols in which the same antigens were used in combination with the adjuvant DDA. Immune responses to immunizing and self PGs and CII, and the incidence, severity, and onset of arthritis were monitored throughout the experiments. In addition, a new, inexpensive, and powerful method of inducing arthritis using crude cartilage extracts is described. RESULTS: A significantly reduced onset period and a more severe arthritis were achieved in BALB/c mice immunized with cartilage PGs in DDA. PGs from bovine, ovine, and porcine cartilage, which otherwise have no effect or have only a subarthritogenic effect, and crude extracts of human osteoarthritic cartilage induced a 100% incidence with a very high arthritis score in BALB/c mice. The overall immune responses to either CII or PG were similar in antigen/CFA-immunized and antigen/DDA-immunized animals, but the Th1/Th2 balance shifted significantly toward a Th1 bias in DDA-injected animals with either PGIA or CIA. CONCLUSION: DDA, which was first used in autoimmune models, is a potent nonirritant adjuvant, which eliminates all undesired side effects of the Freund's adjuvants. DDA exerts a strong stimulatory effect via the activation of nonspecific (innate) immunity and forces the immune regulation toward Th1 dominance. These lines of evidence also suggest the possibility that seemingly innocuous compounds may exert an adjuvant effect in humans and may create the pathophysiologic basis of autoimmunity in susceptible individuals via the activation/stimulation of innate immunity.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Arthritis And Rheumatism. - 50 : 5 (2004), p. 1665-1676. -
További szerzők:Berlo, Suzanne E. Szántó Sándor (1968-) (belgyógyász, reumatológus) Broeren, Chris P. M. Mikecz Katalin Glant Tibor T.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM105027
035-os BibID:(cikkazonosító)152109 (WoS)001042945400005 (Scopus)85140434684
Első szerző:Hartman, Linda
Cím:Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+ : the pragmatic, multicenter, placebo-controlled GLORIA trial / L. Hartman, M. El Alili, M. Cutolo, D. Opris, J. A. P. Da Silva, Z. Szekanecz, F. Buttgereit, P. Masaryk, R. Bos, M. R. Kok, S. Paolino, V. M. H. Coupè, W. F. Lems, M. Boers, GLORIA consortium
Dátum:2022
ISSN:0049-0172
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Seminars In Arthritis And Rheumatism. - 57 (2022), p. 1-8. -
További szerzők:El Alili, M. Cutolo, Maurizio Opris, Daniela (1976-) (reumatológus) Da Silva, J. A. P. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Buttgereit, Frank Masaryk, Pavol Bos, Reinhard Kok, Marc R. Paolino, Sabrina Coupé, V. M. H. Lems, Willem F. Boers, Maarten GLORIA Trial consortium
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

12.

001-es BibID:BIBFORM072682
Első szerző:Hudson, Marie
Cím:Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis : results from the International Scleroderma Renal Crisis Survey / Hudson Marie, Baron Murray, Tatibouet Solène, Furst Daniel E., Khanna Dinesh, International Scleroderma Renal Crisis Study Investigators
Dátum:2014
ISSN:0049-0172
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
scleroderma renal crisis
Megjelenés:Seminars In Arthritis And Rheumatism. - 43 : 5 (2014), p. 666-672. -
További szerzők:Baron, Murray Tatibouet, Solène Furst, Daniel E. Khanna, Dinesh Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) International Scleroderma Renal Crisis Study Investigators
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2 3 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.